指南与共识肝病消化道肿瘤与早癌

免疫检查点抑制剂肝毒性:系统综述与管理建议

Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
指南 / 共识 · Hepatology · 2020-01-01

免疫检查点抑制剂(ICI)广泛用于晚期恶性肿瘤,肝毒性是重要免疫相关不良反应,发生率高达16%。本综述系统回顾ICI诱导的免疫介导性肝毒性(IMH)证据,总结诊断与管理策略,并提供诊断和管理算法。

要点

  • ICI相关肝毒性发生率高达16%,需常规监测肝功能。
  • 管理IMH需熟悉诊断流程、治疗选择及ICI剂量调整策略。
  • 本综述提供IMH诊断与管理算法,辅助临床决策。

核心结论

  • ICI诱导的免疫介导性肝毒性是重要不良反应,优化患者结局需熟悉其诊断与管理。

研究设计与样本

  • 系统综述,旨在全面回顾IMH证据、系统评价其管理并呈现诊断与管理算法。

主要发现

  • 肝毒性发生在高达16%接受ICI治疗的患者中。

临床怎么用

  • 接受ICI治疗的患者需 awareness 和熟悉IMH的诊断与管理,包括治疗方法和ICI剂量管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies. The advent of ICIs has been a major breakthrough in the field of oncology, a fact recognized by the 2018 Nobel Prize in Physiology or Medicine being awarded for the discovery. The Food and Drug Administration approved the first ICI, ipilimumab, in 2011 for the treatment of metastatic melanoma. Seven ICIs are now used in clinical practice, including nivolumab and pembrolizumab for treatment of advanced hepatocellular carcinoma. ICIs are increasingly used across the spectrum of hepatobiliary neoplasia. The utility of ICI therapy has been limited by immune-related adverse reactions (irAEs) affecting multiple organ systems. Hepatotoxicity is an important irAE, occurring in up to 16% of patients receiving ICIs. Optimizing outcomes in patients receiving ICI therapy requires awareness of and familiarity with diagnosing and management of ICI-induced immune-mediated hepatotoxicity (IMH), including approaches to treatment and ICI dose management. The aim of this review article is to (1) provide a comprehensive, evidence-based review of IMH; (2) perform a systematic review of the management of IMH; and (3) present algorithms for the diagnosis and management of IMH.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Peeraphatdit TB, Wang J, Odenwald MA, et al. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatology. 2020. PMID: 32167613. doi:10.1002/hep.31227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。